Increasing numbers of women of childbearing age in the Southeastern US are becoming infected with HIV. If these women become pregnant and are relatively healthy with no signs or symptoms of AIDS, ACTG 076 (AIDS Clinical Trial Group) dramatically demonstrated that a 3-part regimen of zidovudine (ZDV) administered to the mother orally during pregnancy, intravenously during labor, then orally to the infant, resulted in a reduction of transmission of HIV to the infants from 25% in the control group to 8% in the group receiving the study treatmeent. This study is being conducted as part of the multicenter pediatric ACTG and is designed to determine if hyper immune globulin to HIV (HIVIG) given to the pregnant woman and infant in addition to the ADV regimen used in ACTG 076 will reduce the transmission of HIV to infants in sicker mothers than those participating in ACTG 076. Future plans iinlcude enrollment of other pregnant HIV infected women into phase I, II, or III studies of the PACTG as they become available, and to continue to encourage pregnant women with HIV to receive care for themselves and their infants so that they may have access to participation in clinical research studies around the issue of perinatal infection and/or treatment of infected children.
Showing the most recent 10 out of 570 publications